Genvoya

Active ingredients · Cobicistat, Elvitegravir, Emtricitabine, Tenofovir Alafenamide Fumarate

Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide · Tablet · 150 mg / 150 mg

NDC

61958-1901

Route

Oral

Therapeutic class

Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A Inhibitor , Cytochrome P450 3A Inhibitors [MoA], HIV Integrase Inhibitors [MoA], Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor , Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor , Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor , Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor , Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleoside Reverse Transcriptase Inhibitors [MoA], Nucleosides [CS], Nucleosides [CS], Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA], Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]

Marketing category

NDA